| Date | Title | Description |
| 10.09.2024 | Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer | Industry veteran Daoud brings more than 25 years' experience in business development and corporate finance and strategy at multiple leading biopharmaceutical organizations
WALTHAM, Mass., Sept. 10, 2024 /PRNewswire/ -- Affinia Therapeutics ... |
| 16.07.2012 | 4 ways to think about GSK’s $3.6B offer for Human Genome Sciences | It has taken a few months and some hand-wringing, but Human Genome Sciences (NASDAQ:HGSI) has agreed to a $3.6 billion offer from GlaxoSmithKline (NYSE:GSK) after a three-month stand-off courtship. It’s yet another example of the deal-makin... |
| 08.06.2012 | Less than 1% of HGSI shares tendered for sale; GSK extends $2.6B offer | While GSK is trying to secure a sale within this month, HGS has a different timeline in mind. The company had adopted a “poison pill” provision that would dilute GSK’s holdings in the event that the British pharmaceutical giant went forward... |
| 30.05.2012 | GSK aims to replace entire HGSI board with its own nominees | The sources told Reuters that GSK is expected to extend the deadline. In coming weeks, the company will seek shareholder consent to replace the board. In the meantime, GSK has already started reaching out to executives in the pharmaceutical... |
| 29.05.2012 | HGSI shareholder sues, says board’s poison pill holds shareholders hostage | The suit Duane Howell, individually and all others similarly situated v. H. Thomas Watkins, et al, was filed last Friday in circuit court for Montgomery County, Maryland.
GSK and HGS are partnered on lupus drug Benlysta as well as late-stag... |
| 23.05.2012 | GSK seeks remedy for HGSI poison pill but offer and deadline still stand | GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, said today that because of the poison pill, its tender offer comes with an added condition that requires HGS “to redeem the pill.” In other words, GSK wants act... |
| 17.05.2012 | HGSI thwarts GSK takeover with poison pill, buys time to seek other offers | If the British pharma giant gets a 15 percent or greater stake in HGS without board approval, the shareholder rights plan gives HGS stockholders the right to purchase additional shares at a discount, which would dilute GSK’s holdings. This ... |
| 09.05.2012 | GSK starts $2.6B HGSI bid; HGSI will respond in 10 business days | GlaxoSmithKline‘s (NYSE:GSK) forced Human Genome Sciences’ (NASDAQ:HGSI) hand and now the biotechnology company must make a decision about its future on a much faster timetable than it would have liked.
GSK today formally commenced its offe... |
| 25.04.2012 | Witty on GSK’s HGSI bid: ‘We are the compelling owner for this business’ | GlaxoSmithKline (NYSE:GSK) stood ready to field questions about its first quarter financial earnings but everyone seemingly wanted to ask CEO Andrew Witty about the pharmaceutical giant’s $2.6 billion bid to buy Human Genome Sciences (NASDA... |
| 19.04.2012 | GSK’s Witty tells HGSI’s Watkins, ‘the logic of this combination is clear for both companies …’ | Witty asked for a response by April 19. He got that response today as the company essentially said GSK’s offer was not enough. In confirming its offer for HGS, GSK also provided the text of Witty’s letter to Watkins:
11 April 2012
Dear Tom
... |
| 19.04.2012 | HGSI rejects GSK’s $2.6B bid, says offer doesn’t reflect the biotech’s value | A GSK acquisition of its drug partner HGS has been rumored for years. The partnership’s most visible product is Benlysta, the lupus drug that became the first new lupus treatment in more than 50 years when it was approved by the U.S. Food a... |
| 18.04.2012 | GSK, FivePrime partner to discover new asthma and COPD treatments | Over the next four years, privately held FivePrime stands to gain up to $30 million from the new deal in the form of up-front payments, GSK purchase of FivePrime equity, research funding and option payments related to the program. FivePrime... |
| 03.04.2012 | GSK says diabetes drug’s initial phase 3 results support regulatory filing | The remaining phase 3 clinical trials on albiglutide suggest that the GSK diabetes treatment still shows promise. Britain-based GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, did not release additional detai... |
| 12.08.2011 | Benlysta benchmarks: Progress of the GSK-HGSI lupus treatment so far | “The fundamentals of the Benlysta launch are positive,” said GSK spokeswoman Holly Russell. “The HGS and GSK sales teams have called on 90 percent of the key rheumatology accounts with awareness of Benlysta among rheumatologists at virtuall... |
| 14.07.2011 | Lupus drug Benlysta gets European approval for GSK, HGSI | “The European approval of Benlysta represents a significant milestone, and we are very pleased to be able to provide physicians an additional therapeutic option for treating appropriate patients with this chronic disease,” Dr. Tony Hoos, GS... |
| 12.07.2011 | GSK’s lupus drug Benlysta gets Health Canada approval | Lupus is an autoimmune disease in which the body attacks its own tissues and affects the organs. Pain and inflammation typically result, as well as extreme fatigue, unexplained fever, skin rashes and kidney problems. The disease affects wom... |
| 10.03.2011 | GSK’s Benlysta: The new face of a ‘blockbuster’ drug (with more to come) | Years before Benlysta’s approval as the first new lupus treatment in more than 50 years, GlaxoSmithKline (NYSE:GSK) signed a development and commercialization agreement with Human Genome Sciences (NASDAQ:HGSI) in which the two companies wou... |
| 09.03.2011 | FDA approves GSK lupus drug Benlysta | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 22.01.2008 | Life sciences briefing: Tuesday, Jan. 22, 2007 | TODAY’S HEADLINES:
Teva acquires protein-therapeutic maker CoGenesys for $400M (release)
ViewRay takes in $25M for MRI radiation-therapy guidance (release)
NovaMed, Chinese clinical-research outfit, receives $14M (release)
Progentix Ortho r... |
| 10.12.2007 | The fundamental biology of making biotech proteins without cells, courtesy of Fundamental Applied Biology | Biotechnology owes its birth as an industry to the discovery of recombinant DNA, which allowed researchers to make particular proteins by tinkering with cellular genomes. Inserting the gene for human insulin into a bacterial cell, for insta... |
| - | HGSI shareholder sues, says board’s poison pill holds shareholders hostage | Not all Human Genome Science (NASDAQ:HGSI) shareholders agree with the company position that GlaxoSmithKline‘s (NYSE:GSK) $2.6 billion purchase offer is insufficient.
An HGS shareholder has filed a suit against the board and asked a court t... |
| - | FDA approves GSK lupus drug Benlysta | Lupus drug Benlysta has been approved by the Food and Drug Administration, becoming the first new lupus drug approved in 56 years.
The intravenous drug was developed by Maryland-based Human Genome Sciences (NASDAQ:HGSI) and GlaxoSmithKline ... |
| - | GSK seeks remedy for HGSI poison pill but offer and deadline still stand | GlaxoSmithKline (NYSE:GSK) has made a change in its offer to buy Human Genome Sciences (NASDAQ:HGSI), but it’s not sweetening the price.
The British pharmaceutical giant announced that it is amending the conditions of its cash offer to acqu... |
| - | Lupus drug Benlysta gets European approval for GSK, HGSI | Lupus drug Benlysta is two-for-two this week.
GlaxoSmithKline (NYSE:GSK) and drug partner Human Genome Sciences (NASDAQ:HGSI) said Thursday that the European Commission has granted marketing authorization for Benlysta, an announcement that ... |
| - | GSK says diabetes drug’s initial phase 3 results support regulatory filing | GlaxoSmithKline’s (NYSE:GSK) experimental type 2 diabetes treatment albiglutide now has initial results from its seven remaining phase 3 studies of the compound and the company says the data support moving toward a regulatory filing for the... |
| - | GSK starts $2.6B HGSI bid; HGSI will respond in 10 business days | GlaxoSmithKline‘s (NYSE:GSK) forced Human Genome Sciences’ (NASDAQ:HGSI) hand and now the biotechnology company must make a decision about its future on a much faster timetable than it would have liked.
GSK today formally commenced its offe... |
| - | GSK, FivePrime partner to discover new asthma and COPD treatments | GlaxoSmithKline (NYSE:GSK) is partnering with California biotechnology company Five Prime Therapeutics to discover new treatments for respiratory disorders.
It’s the second drug discovery alliance in two years that involves the companies. I... |
| - | GSK aims to replace entire HGSI board with its own nominees | If you expected the merger and acquisition standoff between GlaxoSmithKline (NYSE:GSK) and Human Genome Sciences (NASDAQ:HGSI) to come to a resolution next week, think again.
GSK plans to replace HGS’ entire 12-member board with its own sla... |
| - | Witty on GSK’s HGSI bid: ‘We are the compelling owner for this business’ | GlaxoSmithKline (NYSE:GSK) stood ready to field questions about its first quarter financial earnings but everyone seemingly wanted to ask CEO Andrew Witty about the pharmaceutical giant’s $2.6 billion bid to buy Human Genome Sciences (NASDA... |
| - | GSK’s lupus drug Benlysta gets Health Canada approval | Lupus drug Benlysta, developed by GlaxoSmithKline (NYSE:GSK) and drug partner Human Genome Sciences (NASDAQ:HGSI), can now count Canada among the markets where it will offer the first new lupus treatment in nearly 50 years.
The companies on... |
| - | GSK’s Witty tells HGSI’s Watkins, ‘the logic of this combination is clear for both companies …’ | GlaxoSmithKline‘s (NYSE:GSK) courtship of Human Genome Sciences (NASDAQ:HGSI) started with a phone call and then a letter on April 11.
GSK CEO Andrew Witty told his counterpart at HGS, Tom Watkins, that the company would offer $13 per share... |
| - | Benlysta benchmarks: Progress of the GSK-HGSI lupus treatment so far | It’s been five months since new lupus drug Benlysta became the first new U.S. Food and Drug Administration-approved lupus treatment in 56 years. Since receiving FDA approval, GlaxoSmithKline (NYSE:GSK) and drug partner Human Genome Sciences... |
| - | 4 ways to think about GSK’s $3.6B offer for Human Genome Sciences | It has taken a few months and some hand-wringing, but Human Genome Sciences (NASDAQ:HGSI) has agreed to a $3.6 billion offer from GlaxoSmithKline (NYSE:GSK) after a three-month stand-off courtship. It’s yet another example of the deal-makin... |
| - | HGSI thwarts GSK takeover with poison pill, buys time to seek other offers | Unless GlaxoSmithKline (NYSE:GSK) sweetens its offer to buy Human Genome Sciences (NASDAQ:HGSI), a hostile takeover will come with a bitter taste.
In rejecting GSK’s nearly $2.6 billion offer today, HGS’ board of directors also adopted a “p... |
| - | GSK’s Benlysta: The new face of a ‘blockbuster’ drug (with more to come) | Years before Benlysta’s approval as the first new lupus treatment in more than 50 years, GlaxoSmithKline (NYSE:GSK) signed a development and commercialization agreement with Human Genome Sciences (NASDAQ:HGSI) in which the two companies wou... |
| - | HGSI rejects GSK’s $2.6B bid, says offer doesn’t reflect the biotech’s value | Human Genome Sciences‘ (NASDAQ:HGSI) response to GlaxoSmithKline‘s (NYSE:GSK) unsolicited $2.6 billion buyout offer is succinct and direct: It’s not enough.
The Maryland company, a longtime drug partner to GSK, disclosed today that the Brit... |
| - | Less than 1% of HGSI shares tendered for sale; GSK extends $2.6B offer | GlaxoSmithKline‘s (NYSE:GSK) $2.6 billion offer to buy Human Genome Sciences (NASDAQ:HGSI) has enticed holders of 474,029 shares of the Maryland biotechnology company to tender their stock for the sale.
The remaining shareholders now have t... |
